Jacobs Levy Equity Management
CLSD

Jacobs Levy Equity Management’s Clearside Biomedical CLSD Stock Holding History

Jacobs Levy Equity Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,059
Closed -$282K – 990
2018
Q3 		$282K Buy
+3,059
New +$364K ﹤0.01% 876

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's CLSD Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 3,059 shares — an estimated $282K sold.

Jacobs Levy Equity Management first reported a position in CLSD in Q3 2018 and held it in 1 quarter. The position peaked at $282K in Q3 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • Jacobs Levy Equity Management reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,059 Clearside Biomedical shares in Q4 2018, an estimated $282K.
  • Jacobs Levy Equity Management first reported a position in Clearside Biomedical in Q3 2018 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Clearside Biomedical position peaked at $282K in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.